Abstract
Bisphosphonates are the standard of care for preventing skeletal morbidity in patients with malignant bone disease. In this setting, zoledronic acid (intravenous; 4 mg monthly) is approved for the prevention of skeletal-related events in patients with bone lesions from multiple myeloma or bone metastases from breast cancer and other solid tumors (eg, genitourinary malignancies, lung cancer). Recent data from large phase III studies show that zoledronic acid (4 mg every 6 months) preserves bone mineral density and reduces disease recurrence in bone and at other sites during adjuvant endocrine therapy for early breast cancer in both pre- and postmenopausal women. There is a strong preclinical and early clinical rationale that zoledronic acid can inhibit cancer cell proliferation and viability and interfere with various steps in the metastatic process (effects on the cancer “seed”). In addition, bisphosphonates alter bone metabolism and may render the bone microenvironment (“soil”) less conducive to tumor growth. This article will summarize the current evidence in the context of the “seed and soil” theory of tumor metastasis, and will discuss how emerging new data and ongoing trials of bisphosphonates for the prevention of metastases in various tumor types might expand their role in the adjuvant therapy setting.
Keywords: Adjuvant therapy, antitumor, bisphosphonate, bone metastases, zoledronic acid, Breast cancer, ABC transporters, MDR phenotype, endocrine regulation, chemotherapeutic agents, tamoxifen, doxorubicine, epirubicin, methotrexate, fluorescent, ATP hydrolysis, electrospray ionization, Atomic absorption spectroscopy, Cisplatin, Carboplatin, Gemcitabine, Cyclophosphamide, Vinorelbine
Current Cancer Therapy Reviews
Title: Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Volume: 7 Issue: 2
Author(s): Michael Gnant
Affiliation:
Keywords: Adjuvant therapy, antitumor, bisphosphonate, bone metastases, zoledronic acid, Breast cancer, ABC transporters, MDR phenotype, endocrine regulation, chemotherapeutic agents, tamoxifen, doxorubicine, epirubicin, methotrexate, fluorescent, ATP hydrolysis, electrospray ionization, Atomic absorption spectroscopy, Cisplatin, Carboplatin, Gemcitabine, Cyclophosphamide, Vinorelbine
Abstract: Bisphosphonates are the standard of care for preventing skeletal morbidity in patients with malignant bone disease. In this setting, zoledronic acid (intravenous; 4 mg monthly) is approved for the prevention of skeletal-related events in patients with bone lesions from multiple myeloma or bone metastases from breast cancer and other solid tumors (eg, genitourinary malignancies, lung cancer). Recent data from large phase III studies show that zoledronic acid (4 mg every 6 months) preserves bone mineral density and reduces disease recurrence in bone and at other sites during adjuvant endocrine therapy for early breast cancer in both pre- and postmenopausal women. There is a strong preclinical and early clinical rationale that zoledronic acid can inhibit cancer cell proliferation and viability and interfere with various steps in the metastatic process (effects on the cancer “seed”). In addition, bisphosphonates alter bone metabolism and may render the bone microenvironment (“soil”) less conducive to tumor growth. This article will summarize the current evidence in the context of the “seed and soil” theory of tumor metastasis, and will discuss how emerging new data and ongoing trials of bisphosphonates for the prevention of metastases in various tumor types might expand their role in the adjuvant therapy setting.
Export Options
About this article
Cite this article as:
Gnant Michael, Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil, Current Cancer Therapy Reviews 2011; 7 (2) . https://dx.doi.org/10.2174/1573394711107020111
DOI https://dx.doi.org/10.2174/1573394711107020111 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) A Review on Onychine and its Analogs: Synthesis and Biological Activity
Current Organic Synthesis Clinical Next Generation Sequencing for Precision Medicine in Cancer
Current Genomics Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Cancer Stem Cells and the Tumor Microenvironment: Soloists or Choral Singers
Current Pharmaceutical Biotechnology Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends
Current Drug Targets Application of Reproductive Hormone Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Reversal of Multidrug Resistance by Natural Substances from Plants
Current Topics in Medicinal Chemistry C-Methionine PET/CT in Central Nervous System Tumours: A Review
Current Radiopharmaceuticals A Comprehensive Overview of the Synthesis of Tetrahydrocarbazoles and its Biological Properties
Mini-Reviews in Organic Chemistry PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Genetic Chemoprotection with Mutant O6-Alkylguanine-DNA-Alkyltransferases
Current Gene Therapy The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy